Bottom line
DLHAX vs ETHSX: the short answer
DLHAX (Nomura Healthcare Fund) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) are both mutual funds.
But DLHAX is far broader, holding 108 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
ETHSX is cheaper at 1.18% vs 1.21% — a difference of $3.00 a year per $10,000 invested.
Over five years, DLHAX returned +6.2% a year vs +5.3% for ETHSX (reporting dates differ).
Updated Nov 19, 2026
DLHAX vs ETHSX side by side
| DLHAX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Voya | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.21% | 1.18% |
| Annual cost per $10k | $121 | $118 |
| 10-yr cost on $10k (prospectus) | $2,006 | $1,911 |
| Max front load | 5.75% | 5.25% |
| 12b-1 fee | 0.25% | 0.25% |
| 1-yr return | +15.1% | −1.9% |
| 5-yr return (annualized) | +6.2% | +5.3% |
| 10-yr return (annualized) | +9.5% | +6.4% |
| Best quarter | +21.5% | +14.2% |
| Worst quarter | −14.9% | −12.1% |
| Net assets (fund) | $750.2M | $757.9M |
| Number of holdings | 108 | 42 |
| Portfolio turnover | 4% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | DLHAX | ETHSX | Difference |
|---|---|---|---|
| 2024 | +8.5% | +3.5% | +5.0% |
| 2023 | +4.2% | +5.7% | −1.5% |
| 2022 | −1.3% | −9.4% | +8.1% |
| 2021 | −5.3% | +22.1% | −27.4% |
| 2020 | +11.1% | +13.0% | −1.9% |
| 2019 | +31.5% | +26.0% | +5.5% |
| 2018 | −0.8% | +6.0% | −6.8% |
| 2017 | +32.0% | +16.2% | +15.7% |
| 2016 | −4.3% | −14.9% | +10.6% |
| 2015 | +11.4% | +8.4% | +3.0% |
Source: Fund prospectus bar charts
Holdings overlap
10 of DLHAX's top 25 holdings also appear in ETHSX's top 25.
| Holding | DLHAX | ETHSX |
|---|---|---|
| Abbvie Inc | 4.19% | 6.46% |
| Eli Lilly & Company | 4.16% | 12.47% |
| Unitedhealth Group Inc | 3.88% | 5.49% |
| Merck & Company Inc | 3.68% | 5.08% |
| Gilead Sciences Inc | 3.54% | 3.34% |
| Astrazeneca Plc | 3.27% | 6.24% |
| Roche Holding Ag | 3.01% | 5.44% |
| Vertex Pharmaceuticals Inc | 1.66% | 3.38% |
| Neurocrine Biosciences Inc | 1.57% | 1.41% |
| Boston Scientific Corp | 1.42% | 2.18% |
Source: SEC Form N-PORT
DLHAX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between DLHAX and ETHSX?
Which is cheaper, DLHAX or ETHSX?
Should I own both DLHAX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.